A phase II study of capecitabine plus gemcitabine in patients with locally advanced or metastatic pancreatic cancer. 2008

Hong Suk Song, and Young Rok Do, and Heung Moon Chang, and Min Hee Ryu, and Kyung Hee Lee, and Yeul Hong Kim, and Dae Sik Hong, and Jae Yong Cho, and Kyoung Eun Lee, and Si Young Kim
Division of Hematooncology, Department of Internal Medicine, Dongsan Medical Center, Keimyung University School of Medicine, Dongsan-Dong, Chung-Gu, Daegu 200-712, South Korea. shs7436@dsmc.or.kr

OBJECTIVE This open-label, multicenter phase II study was conducted to investigate the efficacy and safety of capecitabine plus gemcitabine combination chemotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer. METHODS We enrolled 63 patients who received capecitabine 830 mg/m(2) orally twice daily on days 1-21 plus gemcitabine 1000 mg/m(2) as a 30-min infusion on days 1, 8 and 15 every 4 weeks for up to six cycles. RESULTS A total of 14 patients had partial responses giving an overall response rate of 22% (95% confidence interval [CI] 13-34%) in the intent-to-treat population. The median time to progression and overall survival were 3.9 months (95% CI 3.5-5.7) and 7.5 months (95% CI 5.0-10.0), respectively, and 1-year survival rate was 27.1% in the intent-to-treat population. Capecitabine plus gemcitabine was well tolerated. Grade 3 hematological adverse events were neutropenia (21%) and thrombocytopenia (2%); the only grade 4 hematological events were anemia (2%) and neutropenia (6%). Non-hematological adverse events were mainly gastrointestinal events and hand-foot syndrome, which affected 16% of patients. Grade 3/4 non-hematological events were infrequent. CONCLUSIONS The combination of capecitabine plus gemcitabine appears to be active and well tolerated as first-line treatment in patients with advanced/metastatic pancreatic cancer.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009362 Neoplasm Metastasis The transfer of a neoplasm from one organ or part of the body to another remote from the primary site. Metastase,Metastasis,Metastases, Neoplasm,Metastasis, Neoplasm,Neoplasm Metastases,Metastases
D010190 Pancreatic Neoplasms Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA). Cancer of Pancreas,Pancreatic Cancer,Cancer of the Pancreas,Neoplasms, Pancreatic,Pancreas Cancer,Pancreas Neoplasms,Pancreatic Acinar Carcinoma,Pancreatic Carcinoma,Acinar Carcinoma, Pancreatic,Acinar Carcinomas, Pancreatic,Cancer, Pancreas,Cancer, Pancreatic,Cancers, Pancreas,Cancers, Pancreatic,Carcinoma, Pancreatic,Carcinoma, Pancreatic Acinar,Carcinomas, Pancreatic,Carcinomas, Pancreatic Acinar,Neoplasm, Pancreas,Neoplasm, Pancreatic,Neoplasms, Pancreas,Pancreas Cancers,Pancreas Neoplasm,Pancreatic Acinar Carcinomas,Pancreatic Cancers,Pancreatic Carcinomas,Pancreatic Neoplasm
D010349 Patient Compliance Voluntary cooperation of the patient in following a prescribed regimen. Client Adherence,Client Compliance,Non-Adherent Patient,Patient Adherence,Patient Cooperation,Patient Noncompliance,Patient Non-Adherence,Patient Non-Compliance,Patient Nonadherence,Therapeutic Compliance,Treatment Compliance,Adherence, Client,Adherence, Patient,Client Compliances,Compliance, Client,Compliance, Patient,Compliance, Therapeutic,Compliance, Treatment,Cooperation, Patient,Non Adherent Patient,Non-Adherence, Patient,Non-Adherent Patients,Non-Compliance, Patient,Nonadherence, Patient,Noncompliance, Patient,Patient Non Adherence,Patient Non Compliance,Patient, Non-Adherent,Therapeutic Compliances,Treatment Compliances
D003841 Deoxycytidine A nucleoside component of DNA composed of CYTOSINE and DEOXYRIBOSE. Cytosine Deoxyribonucleoside,Cytosine Deoxyriboside,Deoxyribonucleoside, Cytosine,Deoxyriboside, Cytosine
D005260 Female Females
D005472 Fluorouracil A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid. 5-FU,5-FU Lederle,5-FU Medac,5-Fluorouracil,5-Fluorouracil-Biosyn,5-HU Hexal,5FU,Adrucil,Carac,Efudex,Efudix,Fluoro-Uracile ICN,Fluoroplex,Fluorouracil Mononitrate,Fluorouracil Monopotassium Salt,Fluorouracil Monosodium Salt,Fluorouracil Potassium Salt,Fluorouracil-GRY,Fluorouracile Dakota,Fluorouracilo Ferrer Far,Fluoruracil,Fluracedyl,Flurodex,Haemato-FU,Neofluor,Onkofluor,Ribofluor,5 FU Lederle,5 FU Medac,5 Fluorouracil,5 Fluorouracil Biosyn,5 HU Hexal,Dakota, Fluorouracile,Fluoro Uracile ICN,Fluorouracil GRY,Haemato FU
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

Hong Suk Song, and Young Rok Do, and Heung Moon Chang, and Min Hee Ryu, and Kyung Hee Lee, and Yeul Hong Kim, and Dae Sik Hong, and Jae Yong Cho, and Kyoung Eun Lee, and Si Young Kim
June 2012, Cancer research and treatment,
Hong Suk Song, and Young Rok Do, and Heung Moon Chang, and Min Hee Ryu, and Kyung Hee Lee, and Yeul Hong Kim, and Dae Sik Hong, and Jae Yong Cho, and Kyoung Eun Lee, and Si Young Kim
February 2011, Investigational new drugs,
Hong Suk Song, and Young Rok Do, and Heung Moon Chang, and Min Hee Ryu, and Kyung Hee Lee, and Yeul Hong Kim, and Dae Sik Hong, and Jae Yong Cho, and Kyoung Eun Lee, and Si Young Kim
July 2002, Zhonghua zhong liu za zhi [Chinese journal of oncology],
Hong Suk Song, and Young Rok Do, and Heung Moon Chang, and Min Hee Ryu, and Kyung Hee Lee, and Yeul Hong Kim, and Dae Sik Hong, and Jae Yong Cho, and Kyoung Eun Lee, and Si Young Kim
April 2014, Cancer chemotherapy and pharmacology,
Hong Suk Song, and Young Rok Do, and Heung Moon Chang, and Min Hee Ryu, and Kyung Hee Lee, and Yeul Hong Kim, and Dae Sik Hong, and Jae Yong Cho, and Kyoung Eun Lee, and Si Young Kim
January 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
Hong Suk Song, and Young Rok Do, and Heung Moon Chang, and Min Hee Ryu, and Kyung Hee Lee, and Yeul Hong Kim, and Dae Sik Hong, and Jae Yong Cho, and Kyoung Eun Lee, and Si Young Kim
September 2000, Anti-cancer drugs,
Hong Suk Song, and Young Rok Do, and Heung Moon Chang, and Min Hee Ryu, and Kyung Hee Lee, and Yeul Hong Kim, and Dae Sik Hong, and Jae Yong Cho, and Kyoung Eun Lee, and Si Young Kim
July 2018, American journal of clinical oncology,
Hong Suk Song, and Young Rok Do, and Heung Moon Chang, and Min Hee Ryu, and Kyung Hee Lee, and Yeul Hong Kim, and Dae Sik Hong, and Jae Yong Cho, and Kyoung Eun Lee, and Si Young Kim
September 2007, Cancer chemotherapy and pharmacology,
Hong Suk Song, and Young Rok Do, and Heung Moon Chang, and Min Hee Ryu, and Kyung Hee Lee, and Yeul Hong Kim, and Dae Sik Hong, and Jae Yong Cho, and Kyoung Eun Lee, and Si Young Kim
January 2004, Urologic oncology,
Hong Suk Song, and Young Rok Do, and Heung Moon Chang, and Min Hee Ryu, and Kyung Hee Lee, and Yeul Hong Kim, and Dae Sik Hong, and Jae Yong Cho, and Kyoung Eun Lee, and Si Young Kim
April 2013, Pancreas,
Copied contents to your clipboard!